New Senate Report Puts Avandia Safety in Spotlight Again
This is a discussion on New Senate Report Puts Avandia Safety in Spotlight Again within the Other Clinical Pharmacy News forum, part of the Industry News and Updates category; A new senate report has rekindled debate about the cardiovascular safety of GlaxoSmithKline's diabetes agent, rosiglitazone (Avandia), stating that ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
02-22-2010, 01:39 PM
|
|||
|
|||
New Senate Report Puts Avandia Safety in Spotlight Again
A new senate report has rekindled debate about the cardiovascular safety of GlaxoSmithKline's diabetes agent, rosiglitazone (Avandia), stating that there are "serious health risks" associated with the drug. It also severely condemns company tactics and criticizes the FDA's role in events.
Heartwire More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Estimating generic availability for Actos, Avandia and related combinations | chantell.reagan | Managed Care Pharmacy Administrative Issues | 0 | 03-12-2009 05:40 PM |
| Demand for Cigna Puts Suggests Further Losses | industry_news | Other Clinical Pharmacy News | 0 | 02-27-2009 04:45 PM |
| FDA posts quarterly report of potential safety issues. | industry_news | FDA News | 0 | 09-05-2008 03:28 PM |
| U.S. Flu Pandemic Vaccination Plan Puts Health Care Workers First | industry_news | Other Clinical Pharmacy News | 0 | 07-24-2008 08:29 AM |
| Rare disease puts Phase III vax trial on hold | industry_news | Biotechnology News | 0 | 03-19-2008 09:08 AM |
© 2008 DrugManagementForum™ powered by |
 |